Most of the cell surface antigens present in AML blasts (CD33, CD123, or CLL1) are also present in normal hematopoietic, representing a safety concern, since a prolonged myeloablation would be ultimately fatal. The gene discussed is CD33; the disease is acute myeloid leukemia.